697 results about "Neuroinflammation" patented technology

The invention discloses application and a preparation method of exosome EGF-FGF-EXO containing double growth factors, the exosome EGF-FGF-EXO is uniform in particle size, high in loading efficiency and good in biological activity, the double growth factors comprise an epidermal growth factor EGF and a fibroblast growth factor FGF, and the epidermal growth factor EGF and the fibroblast growth factor FGF are added into the exosome EGF-FGF. The preparation method of the exosome EGF-FGF-EXO comprises preparation of an induced pluripotent stem cell (iPSC) exosome and loading of EGF-FGF, a recombinant epidermal growth factor (EGF) and a fibroblast growth factor (FGF) are loaded on the exosome from iPS-clone 12c, and the exosome product which has high biological activity and is used for treating nervous system diseases of neuroinflammation is prepared. The invention develops a brand new technical path for treatment of nervous system diseases, and in the fields of epilepsy, neurodegenerative diseases, brain injury and the like, the life quality of patients can be improved and important theoretical basis and technical support can be provided for precise medical treatment of nervous system diseases by precisely regulating and controlling neuroinflammation.

The invention discloses bifidobacterium breve and application thereof in relieving Alzheimer's disease, and belongs to the technical field of probiotics. The preparation method comprises the following steps: separating 18 bifidobacterium strains from feces of children aged 0-3 years old, analyzing and identifying the 18 bifidobacterium strains including bifidobacterium longum, bifidobacterium breve and bifidobacterium animalis, and screening out the bifidobacterium breve LE4 with potential Alzheimer's disease relieving capacity through in-vitro oxidation resistance and LPS (Lipopolysaccharide) removal capacity. The method comprises the steps of behavioral experiments (nesting experiments, open field experiments and water maze experiments), histopathologic analysis, molecular biological detection and the like. The multi-target AD intervention effects of improving the cognitive function, reducing A beta deposition and tau protein phosphorylation, relieving neuroinflammation, enhancing synaptic plasticity, repairing intestinal barriers, adjusting intestinal flora and metabolites and the like of the LE4 strain are comprehensively evaluated, and a new strategy is provided for promoting AD micro-ecological treatment.

The invention relates to the field of biological imaging, and particularly discloses an in-vitro cell microenvironment dynamic monitoring method for two-photon frequency domain fluorescence lifetime imaging, which comprises the following steps: S1, by using a two-photon frequency domain fluorescence lifetime imaging TP-FD-FLIM technology, losslessly representing microenvironment change through fluorescence lifetime parameters, and monitoring oxidative stress reaction and neutrophil migration behavior in real time, analyzing the effect of the associated compound in combination with an in-vitro cell model; and S2, based on the physical basis of FD-FLIM, establishing a frequency domain fluorescence lifetime signal processing and analysis system under periodic excitation, analyzing the dynamic correlation characteristics of the phase delay phi and the modulation depth M of a fluorescence signal relative to exciting light, and carrying out quantitative backstepping on molecular lifetime parameters. According to the in-vitro cell microenvironment dynamic monitoring method for two-photon frequency domain fluorescence lifetime imaging provided by the invention, neuroinflammatory response can be observed in a lossless and real-time manner on the subcellular scale.

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention provides an application of Ly93 in preparation of an anti-epileptic seizure drug, and provides a new thought for an epileptic seizure treatment drug. Research results show that the Ly93 can significantly reduce the grade of epileptic seizure in a KA-induced mouse epileptic seizure model, can significantly reduce the duration of PTZ-induced epileptic seizure, can significantly inhibit neuroinflammation in epileptic seizure, and does not affect the weight of a mouse. Therefore, the Ly93 serving as the epileptic seizure treatment medicine is remarkable in effect, relatively good in safety and relatively small in toxic and side effects.

The present invention relates to tetracycline derivatives and their use as medicaments, in particular in the treatment or prevention of diseases selected from the group comprising or consisting of amyloidosis, pain, neurodegenerative diseases and neuroinflammatory diseases.

Novel compounds such as DHMP maintain DHM features and pharmacological activities with increased potency and efficacy, improved water solubility, enhanced bioavailability, increased permeability to the blood brain barrier (BBB), and increased stability. Because DHMP retains the therapeutic activities of DHM and has properties that improve its bioavailability, it can be used as a therapeutic agent for treating Alzheimer's disease-related diseases (ADRD) including Alzheimer's disease (AD), Vascular Dementia, Frontotemporal Dementia (FTD), Mixed Dementia as well as neurodegeneration such as Parkinson's disease. Administration of these compounds result in beneficial pathological changes including reduction of Aꞵ and Tau, improvement of neuroinflammation, reduction of cognitive / memory deficits, as well as improvement of anxiety, depression, and aggression. The disclosed DHM derivatives can also be used to treat sleep disorders, neurological disorders such as PTSD, Autism, Epilepsy / Seizures, and Alcohol Use Disorders (AUD), fetal alcohol syndrome (FAD), substance addictions, and cancers.

The invention discloses a mesenchymal stem cell membrane bionic nano-enzyme for targeted therapy of Parkinson's disease as well as a preparation method and application of the mesenchymal stem cell membrane bionic nano-enzyme. The mesenchymal stem cell membrane bionic nano enzyme comprises an inner core and a mesenchymal stem cell membrane, wherein the inner core is composed of mesoporous polydopamine nanoparticles, and the mesenchymal stem cell membrane coats the inner core. The medicine contains the mesenchymal stem cell membrane bionic nano enzyme. The mesenchymal stem cell membrane bionic nano-enzyme disclosed by the invention shows good biocompatibility, and can be homed to a Parkinson disease region in the brain under the mediation of CXCR4 and VLA-4 specific membrane proteins. In addition, through the CD47 membrane protein expressed on the surface, the removal of the immune system can be avoided, so that the action time in the body is prolonged. The nano-enzyme is helpful for eliminating reactive oxygen free radicals, reducing oxidative stress level and reducing damage of neuroinflammation to dopaminergic neurons, so that safe and efficient treatment of Parkinson's disease is realized.

The invention provides an application of a pentacyclic triterpenoid compound targeting hydroxyl steroid 17-beta dehydrogenase 4. The pentacyclic triterpenoid compound can effectively relieve or treat central nervous system diseases (inflammatory diseases), including central nervous system degenerative diseases or chronic central inflammatory diseases. The pentacyclic triterpenoid compound can maintain the structural stability or activity of hydroxysteroid 17-beta dehydrogenase and maintain the stability or activity of peroxisome, thereby relieving or treating central nervous inflammation. The pentacyclic triterpenoid compound can target hydroxysteroid 17-beta dehydrogenase 4, inhibit neuroglial cell excessive activation related neuroinflammation, relieve neuron damage or death speed and improve a central nervous system cell metabolism microenvironment.

The invention relates to the technical field of biological medicines, in particular to Hangzhou white chrysanthemum-derived exosome-like nano-vesicles as well as a preparation method and application thereof. Chrysanthemum morifolium ramat nano-vesicles are prepared from compositae plants through a high-speed centrifugation method, the average particle size of the nano-vesicles is 68 nm, and the Zeta potential is-19.50 + / -1.10 mV. The nano vesicles can effectively protect nerve cells and improve anxiety behaviors and cognitive impairment of SAE mice. The compound has a good application prospect in preparation of medicines for treating neuroinflammation and SAE.

The invention discloses preparation and application of dual-network hydrogel. The dual-network hydrogel comprises the following components: (Z1) a spinal cord acellular matrix network DSM formed by self-assembly of a spinal cord acellular matrix dSECM; and (Z2) a metal-polyphenol network MPN formed by coordination of metal ions and polyphenols; wherein the DSM and the MPN are cross-linked through hydrogen bonds to jointly form a double-network structure. DSM provides a microenvironment suitable for cell survival and growth for the dual-network hydrogel and induces stem cells to differentiate into neurons, and MPN provides the dual-network hydrogel with biological effects of inhibiting inflammation and accumulation of reactive oxygen species (ROS). The dual-network hydrogel has the advantages of the two components, the active component neurotrophic factor and the inhibitor loaded on the dual-network hydrogel can regulate and control immune response after SCI, improve neuroinflammation microenvironment and promote nerve repair, and a new strategy is provided for in-situ tissue repair of SCI.

The invention discloses application of a plant lactobacillus CCFM1357 to conversion of anthocyanin to generate various active metabolites, inhibition of a cGAS-STING pathway and enhancement of improvement of brain aging, and belongs to the technical field of microorganisms and the technical field of medicines. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention have the following effects: (1) a marker for relieving D-gal induced mouse brain senescence and a marker for relieving D-gal induced mouse brain senescence; (2) promoting and relieving D-gal induced mouse histopathologic characterization; (3) relieving D-gal induced mouse neuroinflammation; (4) relieving behavioral characterization of the D-gal induced aging mouse; and (5) a cGAS-STING signal channel is inhibited. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention can be used for a product for relieving brain aging, and have a huge application prospect.

The invention discloses a TREM-1 inhibitory peptide nano-particle which is prepared by the following steps: by taking a dendritic polymer PAMAM as a carrier, coupling a TREM-1 inhibitory peptide with amino groups on the carrier by utilizing the characteristic of polyamino groups on the surface of the PAMAM, and coupling a brain-targeted peptide with the other part of amino groups on the carrier through MAL-PEG2000-NHS, so as to obtain the TREM-1 inhibitory peptide nano-particle. And modifying the residual amino groups on the carrier with PEG (Polyethylene Glycol) to obtain the nano-particles. The nanoparticles can relieve encephaledema, neuroinflammation injury and blood brain barrier damage caused by traumatic craniocerebral injury, improve cognitive impairment and long-term prognosis after trauma, and have a very high curative effect on clinical treatment of craniocerebral injury.

The invention relates to the field of chemical analysis, and particularly discloses a method for detecting indole and derivatives thereof in serum and excrement. Before liquid chromatography-mass spectrometry detection, a methanol-water mixed solvent is adopted for extraction, and freeze grinding, ultrasonic treatment, standing, centrifugation and other steps are carried out. According to the pretreatment process, the influences of complex matrixes and more interfering substances are eliminated, more tryptophan metabolites are detected at the same time, the adopted pretreatment mode is simple, low in cost and environmentally friendly, and qualitative and quantitative detection of indole and derivatives thereof in complex biological samples can be achieved. The indole derivative has important significance in the fields of enhancing the integrity of the intestinal epithelial barrier, inhibiting neuroinflammation, improving insulin resistance and regulating and controlling the polarization direction of immune cells based on deep research of indole and the indole derivative.

The invention discloses design and synthesis of a series of brain-targeted ginsenoside Rg1 derivatives and application of the brain-targeted ginsenoside Rg1 derivatives in treatment of Alzheimer's disease. According to the invention, ginsenoside Rg1 and polyethylene glycol with a specific chain length are covalently linked to successfully construct the derivative capable of enhancing the penetrating power of the blood-brain barrier. The series of derivatives provided by the invention not only solve the problems of poor brain targeting and insufficient stability of natural Rg1, but also can inhibit neuroinflammation by regulating and controlling an NLRP3 / caspase-1 signal channel in an LPS-induced neuroinflammation model, and finally, the learning and memory ability is remarkably improved. The product is simple and convenient in preparation process and good in biological safety, and a new candidate compound is provided for developing a new generation of Alzheimer disease treatment medicines.

The invention belongs to the field of biological medicine, and provides preparation of a targeting hepcidin biological agent and application of the targeting hepcidin biological agent in relieving neuropathic pain. According to the invention, a new analgesic target, namely, Hamp, in the spinal cord is found for the first time, and the Hamp is abnormally highly expressed in the spinal cord of a pain model rat. A small interfering RNA (siRNA) targeting Hamp is designed, when the substance is applied to the spinal cord, cell ferroptosis and neuroinflammation in the spinal cord of a rat can be remarkably inhibited, and the substance has a remarkable analgesic effect on mechanical pain sensitivity and crymodynia sensitivity.

The invention provides bacillus licheniformis F0726 for improving neuroinflammation of Alzheimer's disease and application of the bacillus licheniformis F0726. Relates to the microbial field. Experiments prove that the bacillus licheniformis F0726 can improve spatial learning and memory impairment of AD model mice and reduce TNF-alpha and IL-1beta in serum of the AD mice in Alzheimer's disease model mice induced by injecting A beta oligomer into the brain; according to the invention, the content of IL-10 is increased, the alteration of AD mouse intestinal flora is improved, and a new way and potential probiotic resources are provided for developing medicines related to prevention and treatment of Alzheimer's disease.

A method is provided for treating or preventing alcohol dependence and / or an alcohol associated disease or condition. Such a method includes administrating a pharmaceutical composition comprising an effective amount of a compound having formula (I):or a hydrates, a solvate, a pharmaceutically acceptable salt, a prodrug, or a complex thereof to a subject in need thereof. For example, (3S, 4R)-3-((R)-(1-hydroxy-ethyl)-4-((R)-[1-methyl-2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-azetidin-2-one (MC-100093) is an exemplary compound. The composition can be used to prevent or treat alcohol dependence, attenuate alteration in glutamate transporters, reduce alcohol associated neuroinflammation, and treat or prevent alcohol associated fatty liver diseases.

The invention discloses application of LW6 in preparation of drugs for preventing and treating neuroinflammation and protecting microglial cells. Cell experiments prove that the LW6 can inhibit the expression of HIF-1alpha protein in LPS-induced microglial cells BV2, can inhibit the mRNA expression level of inflammatory factors IL-1beta and IL-6 in the microglial cells BV2, and can inhibit the mRNA expression level of microglial cell inflammatory enzyme iNOS, which indicates that the LW6 can protect the microglial cells and prevent and treat neuroinflammation, and has a significant effect on degenerative diseases such as Alzheimer's disease. The compound has certain significance in treating Parkinson's disease, and can be used for preparing medicines for preventing and treating neuroinflammation and medicines for protecting microglial cells.

The invention discloses application of walnut peptide in preparation of a medicine for treating or preventing cognitive impairment of diabetes mellitus. The preparation process of the walnut peptide is as follows: after walnut protein is subjected to enzymolysis by alkaline protease, the molecular weight cut-off is 1t; and separating by using a 3kDa ultrafiltration tube to obtain the walnut peptide. The walnut peptide can effectively reduce the blood sugar level of a diabetic model mouse, regulate the disorder effect of blood fat, relieve brain tissue oxidative damage and hippocampal neuroinflammation damage of the diabetic model mouse, and improve learning and memory damage. The compound can be used for preparing medicines for treating or preventing cognitive impairment of diabetes mellitus.

A Bifidobacterium animalis subsp. lactis for reducing Abeta42 deposition and an application, a name of the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis IOB-LO7, and classified as Bifidobacterium animalis subsp. lactis, the Bifidobacterium animalis subsp. lactis IOB-LO7 is preserved in the General Microbiology Center of the China General Microbiological Culture Collection Center (CGMCC) on Dec. 23, 2021, with the collection number of CGMCC No. 24185. By reducing the levels of Aβ42 in the cerebral cortex and hippocampus, clearing Aβ amyloid plaques, improving communication between neurons, reducing brain neuroinflammation, and protecting nerve cells, it helps to restore cognitive function and improve Alzheimer's disease. Additionally, it can also improve gut microbiota imbalance caused by Alzheimer's disease.

The invention relates to a probiotic preparation for improving Parkinson's disease and an application of the probiotic preparation. The bacterial strains in the probiotic preparation comprise an Ackermania muciniphila Akk11 bacterial strain and a Bifidobacterium breve BBr60 bacterial strain. The invention further relates to a preparation method of the probiotic preparation for improving the Parkinson's disease and an application of the probiotic preparation for improving the Parkinson's disease, wherein the bacterial strains in the probiotic preparation comprise the Ackermania muciniphila Akk11 bacterial strain and the Bifidobacterium breve BBr60 bacterial strain. The invention develops a brand-new probiotic compounding mode and a brand-new probiotic intervention strategy for improving the Parkinson's disease, that is, the Akk11 strain and the BBr60 strain are compounded, and the two strains are found to have potential interaction and can be matched with each other, so that a synergistic effect is achieved on the aspect of improving the Parkinson's disease, and the effect of improving the Parkinson's disease is achieved. Specifically, the traditional Chinese medicine composition synergistically improves dyskinesia caused by Parkinson's disease, reduces expression of related inflammatory factors in nigra, promotes generation of anti-inflammatory factors to relieve neurological inflammation, inhibits activation of inflammasome NLPR3 in nigra, and further inhibits brain inflammation.

The invention discloses application of plasmalogen in preparation of a medicine for promoting spinal cord injury repair. The invention further discloses application of the plasmalogen in preparation of drugs for regulating neuroinflammation or oxidative stress in spinal cord injury. The invention also discloses application of the plasmalogen in preparation of a medicine for promoting motor function recovery after spinal cord injury. The invention further discloses application of the plasmalogen in preparation of a medicine for neuroprotection in spinal cord injury. The invention further discloses application of the plasmalogen to preparation of a medicine for nerve cell myelin sheath regeneration after spinal cord injury. The invention also discloses application of the plasmalogen in preparation of a medicine for promoting nerve fiber regeneration after spinal cord injury. It is found that plasmalogen can effectively reduce the ROS level and regulate and control neuroinflammation and oxidative stress levels, so that neuronal axis mutability and apoptosis are reduced, and neuronal myelin regeneration is promoted.

The invention relates to the technical field of plant extracts, and provides a plant extract composition with synergistic hypoglycemic activity and application thereof, and the plant extract composition comprises a mulberry leaf extract, a white kidney bean extract and bitter gourd powder in a mass ratio of 8: (1-24): (1-64). By optimizing the mass ratio of the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder, the blood sugar reducing effect of the plant extract taking the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder as main raw materials is remarkably superior to that of a plant extract in the prior art. Meanwhile, the plant extract composition also has the effects of synergistically reducing the number of neutrophils around nerves, improving peripheral neuroinflammation, synergistically enhancing the fluorescence intensity of the peripheral nerves, improving peripheral nerve injury and inhibiting the enzymatic activity of a bacterium source dipeptidyl peptidase-4.

The invention relates to a multi-targeting nanogel drug and application thereof in relieving neuroinflammation and promoting spinal cord injury repair, the multi-targeting nanogel drug comprises quercetin-loaded liposome, the quercetin-loaded liposome comprises TAT peptide and CAQK peptide, the quercetin-loaded liposome is incorporated into double-network gel, and the double-network gel is used as a drug carrier. The dual-network gel is jointly formed by a dopamine grafted hyaluronic acid polymer and methacrylated gelatin. The multi-targeting nanogel drug can improve the dissolving property of quercetin, reduce toxic and side effects, promote targeting of an injured part, and contribute to passing through a blood spinal cord barrier, so that the integrity of the blood spinal cord barrier is protected, the spinal cord microenvironment is optimized, formation of glial scars is reduced, axon regeneration is promoted, and the recovery of a motor function is enhanced.

The present invention features compositions and methods for preventing or treating neuroinflammation, amyloidopathy or tauopathy by inhibiting Acyl-CoA:Cholesterol Acyltransferase activity, in particular with brain-permeable inhibitors encapsulated in a stealth liposome-based nanoparticle. Stealth liposome-based nanoparticles for reducing or attenuating amyloidopathy or tauopathy are also provided.

The invention provides application of circular RNA circRNA-APP. Experiments prove that interference of circRNA-APP can significantly reduce expression of hippocampal small proinflammatory factors TNF-alpha and IL-1beta of APP / PS1 TG mice, inhibit generation of A beta and tau phosphorylation, promote expression of anti-inflammatory factors IL-10, inhibit neuronal apoptosis, improve neuronal synaptic structure plastic damage and improve the cognitive function of the APP / PS1 TG mice. The results show that the interference circRNA-APP can inhibit neuroinflammation, thereby inhibiting neuronal apoptosis and synaptic injury, and further improving the cognitive function of AD mice. Therefore, the circular RNA circRNA-APP can serve as a target spot to be used for preparing the medicine for treating or preventing the neurodegenerative diseases, and a new thought is provided for research and development of the medicine for preventing and treating the neurodegenerative diseases including the Alzheimer's disease.

The invention belongs to the technical field of biological medicines, and particularly relates to an active peptide with a function of repairing neuroinflammation after spinal cord injury and a preparation method and application thereof. The invention firstly provides a recombinant active peptide. The structure of the recombinant active peptide at least comprises two groups of alpha spiral fragments; the amino acid sequence of the recombinant active peptide is as shown in SEQ ID NO. 2 or SEQ ID NO. 3. The bioactive peptide and the prepared nanofiber provided by the invention can effectively repair neuroinflammation after spinal cord injury, and have relatively high safety in a living body. And compared with the RK33A holoprotein, the RK33A holoprotein has a better effect.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for relieving side effects of oxaliplatin chemotherapy. The traditional Chinese medicine composition composed of radix paeoniae alba and liquorice is used for relieving various side reactions caused by oxaliplatin, wherein the side reactions comprise peripheral neurotoxicity, hematological toxicity and systemic reaction. The traditional Chinese medicine composition plays a role in relieving peripheral neurotoxicity caused by oxaliplatin through multiple ways, on one hand, neuroinflammatory response in dorsal root ganglions is inhibited, the dorsal root ganglions are responsible for receiving and conducting sensory nerve impulse, the injury is mainly represented as sensory disorders such as numbness of hands and feet, stabbing pain and delayed feeling, and on the other hand, the neuroinflammatory response in the dorsal root ganglions is inhibited; therefore, OIPN can be relieved by inhibiting the inflammatory reaction; on the other hand, the blood flow of microvessels is promoted, and the circulation disorder of the microvessels at the tail ends of the limbs is improved to relieve OIPN. Moreover, the traditional Chinese medicine composition does not influence the anti-tumor effect of oxaliplatin, is good in safety, and does not damage important organs such as heart, liver, spleen, lung and kidney.